HAMBURG, Germany, Aug. 4, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that its research alliance with Boehringer Ingelheim has reached a milestone, triggering a payment of EUR 2.5 million to Evotec. The milestone reached was the selection of a candidate compound for pre-development studies in an inflammation and immunology programme.
